The efficacy of ferric citrate hydrate in chronic kidney disease with mild hyperphosphatemia: randomized controlled open-labeled trial

The efficacy of ferric citrate hydrate in chronic kidney disease with mild hyperphosphatemia: randomized controlled open-labeled trial - FC CKD study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018118

Enrollment

Registered

2015-07-01

Start date

2015-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

predialysis chronic kidney disease (predialysis CKD)

Interventions

CKD patients with mild hyperphosphatemia(P4-6mg/dl) having been under a diet treatment, administered orally ferric citrate hydrate for phosphate normalization. CKD patients with mild hyperphosphatemia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CKD patients with mild hyperphosphatemia(P4-6mg/dl) having been under a diet treatment

Exclusion criteria

Exclusion criteria: 1)impossible dose of ferric citrate hydrate 2)already medicated by other phsphate binders 3)patients participating in other clinical intervention trial 4)presence of severe complication 5)Physician's decision

Design outcomes

Primary

Measure	Time frame
global outcome as both kidney outcome and CVD events.	—

Secondary

Measure	Time frame
renal dysfunction rate, onset of CVD, bone fracture, the frequency of infection, effects of anemia, effects of CKD-MBD, effects of medication	—

Countries

Japan

Contacts

Public ContactHideaki Shima

Osaka Medical College Nephrology

in3130@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026